A top delegation from the east African nation of Zimbabwe – which visited Taizhou city in East China's Jiangsu province on Oct 8 – paved the way for increased international biotech commerce.
During the visit, local vaccine manufacturer Jiangsu Recbio Technology Co Ltd signed a strategic collaboration agreement with the National Biotechnology Authority of Zimbabwe and the China Regional Research Center of the International Center for Genetic Engineering and Biotechnology, or the ICGEB.
The parties sign a strategic cooperation accord. [Photo/WeChat ID: Recbio]
The agreement aims to provide technical support to Zimbabwe for vaccine production, including personnel training, plant designs, clinical trials and technology transfers.
The collaboration will begin with the production of the new crown/herpes zoster vaccine and the HPV vaccine.
The signing of the agreement is said to be a significant milestone for Recbio, demonstrating international recognition of its vaccine R&D and production technology.
The company plans to fully participate in the Belt and Road Initiative and expand its presence in the overseas vaccines market.
The Zimbabwe NBA is a government department dedicated to promoting biotechnology in medicine and agriculture.
ICGEB is an intergovernmental scientific organization that supports research, training and technology transfers in the fields of genetics and biotechnology.
Recbio, founded in 2012, is focused on building innovative vaccines and has a portfolio of vaccines targeting diseases such as cervical cancer, herpes zoster and neococcal pneumonia.
Representatives from China Medical City, a national high-tech zone in Taizhou, attended the signing ceremony.